Lupin completes successful Phase 3 trials for Lucentis biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Executes the first project for developing and manufacturing a novel anticancer mAb
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Subscribe To Our Newsletter & Stay Updated